Want to see TSE:ARCH full AI Analyst Report?

Arch Biopartners (ARCH) Price & Analysis

50 Followers

ARCH Stock Chart & Stats

C$1.37

-C$0.06(-3.14%)

At close: Jan 08 4:00 PM EST

C$1.37

-C$0.06(-3.14%)

Day’s Range― - ―

52-Week RangeC$0.39 - C$1.85

Previous CloseN/A

Volume5.12K

Average Volume (3M)43.97K

Market Cap

C$62.50M

Enterprise ValueC$36.94M

Total Cash (Recent Filing)C$436.76K

Total Debt (Recent Filing)C$2.73M

Price to Earnings (P/E)―

Beta0.73

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding67,933,290

10 Day Avg. Volume31,059

30 Day Avg. Volume43,967

Financial Highlights & Ratios

PEG Ratio0.88

Price to Book (P/B)-21.63

Price to Sales (P/S)0.00

P/FCF Ratio-53.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.16

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Platform Drug Discovery & Focus On Acute InflammationArch’s platform-centered monoclonal antibody discovery and focus on acute inflammation and ARDS create structural optionality: one technology can generate multiple candidates, attract partnerships or licensing, and target high-unmet-need indications where payers and partners seek novel therapies, supporting durable strategic value.

Reduced Debt Versus 2023Material debt reduction is a durable improvement to the capital structure: lower leverage eases short-term financing pressure, reduces fixed obligations, and lengthens runway. This enhances optionality for licensing talks, R&D pacing, or executing partnership deals without immediate refinancing risk.

Narrowing Losses And Improved Cash BurnProgress toward lower operating losses and improved operating cash flow shows tightening cost discipline and slower cash depletion. Sustained improvement reduces near-term funding needs, strengthens bargaining position in partner talks, and increases likelihood that future milestones can be achieved with fewer dilutive financings.

Bears Say

No Current RevenueWith no recurring product sales, Arch depends on partnerships, milestone payments, or external financing. This structural lack of revenue elevates execution and financing risk: clinical progress or licensing delays meaningfully increase the probability of dilution or interrupted development funding over the medium term.

Negative Shareholders' EquityNegative equity signals a thin capital cushion and elevated solvency risk. It constrains borrowing capacity, weakens lender and partner negotiating positions, and raises the likelihood management must raise dilutive capital or pursue non‑core asset transactions to sustain operations, impacting long-term stability.

Ongoing Cash Burn And Volatile FCFPersistent negative operating cash flow and volatile free cash flow reduce predictability for advancing clinical programs. This structural cash flow weakness forces reliance on financing or partnerships, which can delay development timelines, increase dilution risk, and limit strategic flexibility over the coming months.

Arch Biopartners News

Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD

Arch Biopartners (ACHFF) announced that a scientific team led by Dr. Justin Chun at the University of Calgary...

5M ago

Arch Biopartners appoints Patrick Vink as chairman of the board

Arch Biopartners (ACHFF) announced the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors,...

6M ago

Arch granted ethics approval for St. Michaels participation in Phase II trial

Arch Biopartners (ACHFF) announced that the University Health Network Research Ethics Board has granted ethics approval for St....

7M ago

Arch Biopartners’ LSALT Peptide Study: A Promising Step in AKI Prevention

Arch Biopartners (($TSE:ARCH)) announced an update on their ongoing clinical study. Arch Biopartners is conducting a Phase 2...

8M ago

ARCH

ARCH FAQ

What was Arch Biopartners’s price range in the past 12 months?

Arch Biopartners lowest stock price was C$0.39 and its highest was C$1.85 in the past 12 months.

What is Arch Biopartners’s market cap?

Arch Biopartners’s market cap is C$62.50M.

When is Arch Biopartners’s upcoming earnings report date?

Arch Biopartners’s upcoming earnings report date is Aug 27, 2026 which is in 54 days.

How were Arch Biopartners’s earnings last quarter?

Arch Biopartners released its earnings results on Jun 02, 2026. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.

Is Arch Biopartners overvalued?

According to Wall Street analysts Arch Biopartners’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arch Biopartners pay dividends?

Arch Biopartners does not currently pay dividends.

What is Arch Biopartners’s EPS estimate?

Arch Biopartners’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arch Biopartners have?

Arch Biopartners has 67,933,290 shares outstanding.

What happened to Arch Biopartners’s price movement after its last earnings report?

Arch Biopartners reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.769%.

Which hedge fund is a major shareholder of Arch Biopartners?

Currently, no hedge funds are holding shares in TSE:ARCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arch Biopartners Stock Smart Score

Neutral

Insider Transactions

Bought Shares

Worth C$9.0K over
the Last 3 Months

Technicals

Fundamentals

Return on Equity

70.15%

Trailing 12-Months

Asset Growth

-15.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arch Biopartners

Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.